• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.

作者信息

Olsen Mark, Cook Sarah E, Huang Vanthida, Pedersen Niels, Murphy Brian G

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy-Glendale, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA.

Department of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California, One Shields Avenue, Davis, CA 95616, USA.

出版信息

Int J Antimicrob Agents. 2020 Jun;55(6):105964. doi: 10.1016/j.ijantimicag.2020.105964. Epub 2020 Apr 3.

DOI:10.1016/j.ijantimicag.2020.105964
PMID:32251732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7195338/
Abstract
摘要

相似文献

1
Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.观点：基于猫传染性腹膜炎策略的新型冠状病毒肺炎患者潜在治疗选择：中枢神经系统侵袭与药物覆盖范围
Int J Antimicrob Agents. 2020 Jun;55(6):105964. doi: 10.1016/j.ijantimicag.2020.105964. Epub 2020 Apr 3.
2
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.基于结构的虚拟筛选和小分子抑制猫冠状病毒 3CL 蛋白酶的体外检测，作为冠状病毒的替代平台。
Antiviral Res. 2020 Oct;182:104927. doi: 10.1016/j.antiviral.2020.104927. Epub 2020 Sep 7.
3
Current status on treatment options for feline infectious peritonitis and SARS-CoV-2 positive cats.猫传染性腹膜炎和 SARS-CoV-2 阳性猫的治疗选择现状。
Vet Q. 2020 Dec;40(1):322-330. doi: 10.1080/01652176.2020.1845917.
4
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.博赛泼维与 GC376 均可通过靶向作用于 SARS-CoV-2 的主蛋白酶而有效抑制该病毒。
Nat Commun. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x.
5
Purposing Saikosaponins for the treatment of COVID-19.将柴胡皂苷用于治疗新型冠状病毒肺炎。
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
6
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.猫冠状病毒药物可抑制新型冠状病毒的主要蛋白酶并阻断病毒复制。
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
7
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
8
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.肾素-血管紧张素系统抑制在 COVID-19 大流行期间的争议。
Nat Rev Nephrol. 2020 Jun;16(6):305-307. doi: 10.1038/s41581-020-0279-4.
9
Potential Antiviral Options against SARS-CoV-2 Infection.针对 SARS-CoV-2 感染的潜在抗病毒药物选择。
Viruses. 2020 Jun 13;12(6):642. doi: 10.3390/v12060642.
10
In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.计算机辅助的 ADMET 和分子对接研究，寻找来自柠檬苦素和三萜类化合物的 COVID-19 潜在抑制剂。
Comput Biol Med. 2020 Sep;124:103936. doi: 10.1016/j.compbiomed.2020.103936. Epub 2020 Jul 28.

引用本文的文献

1
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.针对严重急性呼吸综合征冠状病毒2型主要蛋白酶（M）的药物和天然产物的计算性重新利用作为潜在的新冠肺炎治疗方法
Front Mol Biosci. 2022 Mar 14;9:781039. doi: 10.3389/fmolb.2022.781039. eCollection 2022.
2
Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.重新利用美国食品和药物管理局批准的药物作为 SARS-CoV-2 主要蛋白酶的潜在抑制剂：改善治疗发现的分子见解。
Comput Biol Med. 2022 Mar;142:105183. doi: 10.1016/j.compbiomed.2021.105183. Epub 2021 Dec 29.
3
Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives.抗击新型冠状病毒肺炎：临床试验、治疗方法与展望
Front Mol Biosci. 2020 Nov 17;7:606393. doi: 10.3389/fmolb.2020.606393. eCollection 2020.
4
How close is SARS-CoV-2 to canine and feline coronaviruses?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与犬猫冠状病毒的亲缘关系有多近？
J Small Anim Pract. 2020 Aug;61(8):523-526. doi: 10.1111/jsap.13207.
5
A Review of Current Interventions for COVID-19 Prevention.当前 COVID-19 预防干预措施综述。
Arch Med Res. 2020 Jul;51(5):363-374. doi: 10.1016/j.arcmed.2020.04.020. Epub 2020 Apr 30.

本文引用的文献

1
Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.预测血管紧张素转化酶 2（ACE2）作为 SARS-CoV-2 受体的利用能力。
Microbes Infect. 2020 May-Jun;22(4-5):221-225. doi: 10.1016/j.micinf.2020.03.003. Epub 2020 Mar 19.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
4
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
5
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.新加坡 2019 年新型冠状病毒肺炎患者的流行病学特征和临床病程
JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.
6
The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients.SARS-CoV2 的神经侵袭性可能在 COVID-19 患者的呼吸衰竭中起作用。
J Med Virol. 2020 Jun;92(6):552-555. doi: 10.1002/jmv.25728. Epub 2020 Mar 11.
7
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
8
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
9
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
10
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.组合筛选一组经 FDA 批准的药物，鉴定出具有抗埃博拉病毒活性的几种候选药物。
Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. doi: 10.1016/j.bbrc.2019.11.065. Epub 2019 Dec 2.